This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe
4 - 6 June, 2024
Excel London Platinum Suite

Marcel Walser, PhD
Senior Director at Molecular Partners AG


Marcel received his MSc in molecular biology and developed novel screening methods for biotechnological applications during his PhD, both at the ETH Zurich, Switzerland. He joined Molecular Partners in 2011. Since then, he led several activities within the Lead Generation Department to enable developable DARPin candidates for various therapeutic programs. During the pandemic, Marcel initiated and lead the pre-clinical activities to generate a clinical DARPin antiviral against SARS-CoV-2. As a co-inventor of the DARPin Switch technology, Marcel is currently driving activities to develop immuno-oncology candidates which are conditionally activated upon antigen binding in the tumor microenvironment.

Agenda Sessions

  • Use of the DARPin Switch Technology to Generate Multi-targeting Immuno-oncology Candidates for Conditional Immune-cell Activation in the Tumor Microenvironment